论文部分内容阅读
肿瘤引流淋巴结(TDLN)是指肿瘤细胞通过淋巴管道所到达的淋巴结,其内包含各类型免疫细胞,如自然杀伤细胞、T细胞、抗原呈递细胞和B细胞.由于这些免疫细胞的存在,以及TDLN位于肿瘤下游这一位置的独特性,使得TDLN成为机体抗肿瘤免疫反应的重要场所;然而TDLN还常常扮演另外一个角色,即对肿瘤产生免疫耐受进而成为肿瘤细胞远组织转移的中转站.在TDLN的免疫治疗中,除常见的离体激活细胞疗法和体内激活细胞疗法外,一些新的治疗方式如靶向治疗等正成为研究热点.本文综述了TDLN的免疫学性质,以及目前与TDLN相关免疫治疗的机制和研究进展.“,”Tumor-draining lymph node,abbreviated as TDLN, refers to the lymph node affected by tumor cells through lymphatic ducts, including various types of immune cells, like nature killer cells, T cells, antigen presenting cells and B cells.Because of the presence of these immune cells and the unique location of TDLN located downstream of the tumor, TDLN becomes an important site of anti-tumor immune response.However, TDLN, often developing immune tolerance to the tumor, becomes the transfer relay station of tumor cells to other tissues.In the immunotherapy of TDLN, except vitro-activate cell therapy and in vivo-activated cell therapy, some new treatments, such as targeted therapy, are becoming the focus of research.This article reviews the immunological properties of TDLN, and the mechanism and research progress of TDLN related immunotherapy.